HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

Lisa Sandmann, Cihan Yurdaydin, Katja Deterding, Benjamin Heidrich, Svenja Hardtke, Patrick Lehmann, Birgit Bremer, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, Benjamin Maasoumy, HIDIT‐II Study Group – 23 September 2021 – Standard treatment of hepatitis delta virus (HDV) infection remains pegylated‐interferon alfa (peg‐IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events.

Impact of Race‐Adjusted Glomerular Filtration Rate Estimation on Eligibility for Simultaneous Liver‐Kidney Transplantation

Sarjukumar Panchal, Marina Serper, Therese Bittermann, Sumeet K. Asrani, David S. Goldberg, Nadim Mahmud – 23 September 2021 – Estimated glomerular filtration rate (eGFR) is adjusted for Black race in commonly used formulas. This has potential implications for access to simultaneous liver‐kidney transplantation (SLKT) as qualifying criteria rely on eGFR.

LiverLearning®: 2021 Webinar: How Patients Can Get Involved with AASLD The Liver Meeting®

The Liver Meeting®, held by the American Association for the Study of Liver Diseases, brings together attendees from around the world to exchange the latest research, discuss new developments in treatments and network with others in the field. This year's annual meeting will be held November 12 - 15, 2021. It will be a digital only meeting. This scientific meeting has expanded greatly in the past few years to include opportunities for patients and patient advocates to engage in meaningful participation.

Subscribe to